Company Overview
Company Type: Private Company
Website: lungpacer.com
Global Number of Employees (Latest): -
Year Founded: 2009
Total Amount Raised (CAD mm)†: 82.32
Total Rounds of Funding**:4
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Lungpacer Medical, Inc. develops a diaphragm pacing therapy system (DPTS) that is used to deliver fluids and medicine to stimulate diaphragm muscles weakened by prolonged time on a ventilator. The company offers Lungpacer DPT System, a diaphragm pacing system for preserving and restoring the strength of the diaphragm muscle in critically ill patients who require mechanical ventilation. Lungpacer Medical, Inc. was founded in 2009 and is based in Exton, Pennsylvania.


Financial Information (Currency: CAD, in mm)
Total Revenue
-
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Global Number of Employees (Latest)
-
Net Debt
-
U.S. Number of Employees 2023
-
U.S. Number of Employees 2022
-
U.S. Last Year Employee Growth %
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Kiple, Chris 
Executive Chairman
Evans, Douglas G.
President, CEO & Director
Hoffer, Joaquín Andrés
Founder and Chief Scientific Officer
Dhavale, Rosemarie 
Vice President of Finance
Fronio, Lesley 
Chief Commercial Officer
Mehta, Nawzer 
Senior Vice President of Clinical Affairs
Conlin, Jonathan 
Corporate Secretary

Key Board Members
Name
Title
Kiple, Chris 
Executive Chairman
Evans, Douglas G.
President, CEO & Director
Donohue, Robert 
Director
Favet, Michael L.
Director
Gordo, Jose Calle
Director
Kaufmann, Joseph W.
Director
Long, Karen M.
Director
Makower, Joshua 
Director
Schroeder, Valeska 
Director


Primary Industry Classification
Health Care Equipment


Primary Office Location
260 Sierra Drive Suite 116 | Exton, PA | 19341 | United States
Phone: 778 655 2100   

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
Keiretsu Capital LLC
-
Unknown
-
-
Medical Technologies Innovators, Inc.
-
Unknown
-
-
New Enterprise Associates, Inc.
-
Unknown
-
-
Valiance Asset Management Limited
-
Unknown
-
-


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Lungpacer Medical USA Inc.

United States and Canada
-
6.00
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Apr-06-2022
-
Private Placement
Target
Lungpacer Medical, Inc.


-
Dec-22-2020
Jan-06-2021
Private Placement
Target
Lungpacer Medical, Inc.


16.00
Apr-30-2019
May-14-2019
Private Placement
Target
Lungpacer Medical, Inc.


45.01
May-24-2017
Jun-09-2017
Private Placement
Target
Lungpacer Medical, Inc.


4.78
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Apr-06-2022
Private Placements
Lungpacer Medical Inc. announced a financing transaction
Feb-14-2022
Product-Related Announcements
Lungpacer Medical Accelerates Pivotal Clinical Study with Aeropace System
Jan-06-2021
Private Placements
Lungpacer Medical Inc. announced that it has received $15.999984 million in funding
Dec-22-2020
Private Placements
Lungpacer Medical Inc. announced a financing transaction
Dec-09-2020
Product-Related Announcements
Lungpacer Medical, Inc. Announces Results of the Rescue 2 Trial


Last 10 Investment Research Documents
No Investment Research returned. This can be caused by entitlement settings or your template settings.


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Key Board Members Details
Name
Title
Phone
Fax
Email
Kiple, Chris 
Executive Chairman
778 655 2100
-

Evans, Douglas G.
President, CEO & Director
778 655 2100
-

Donohue, Robert 
Director
778 655 2100
-

Favet, Michael L.
Director
778 655 2100
-

Gordo, Jose Calle
Director
778 655 2100
-

Kaufmann, Joseph W.
Director
778 655 2100
-
-
Long, Karen M.
Director
778 655 2100
-

Makower, Joshua 
Director
778 655 2100
-
jmakower@nea.com
Schroeder, Valeska 
Director
778 655 2100
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Kiple, Chris 
Executive Chairman
778 655 2100
-

Evans, Douglas G.
President, CEO & Director
778 655 2100
-

Hoffer, Joaquín Andrés
Founder and Chief Scientific Officer
778 655 2100
-
-
Dhavale, Rosemarie 
Vice President of Finance
778 655 2100
-
-
Fronio, Lesley 
Chief Commercial Officer
778 655 2100
-

Mehta, Nawzer 
Senior Vice President of Clinical Affairs
778 655 2100
-

Conlin, Jonathan 
Corporate Secretary
778 655 2100
-

* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
